Relburn is committed to developing innovative products to better the lives of people
with chronic disorders of metabolism. The Company’s lead program is in chronic gout.
Chronic human illness commonly results from dysfunction in multiple physiologic pathways,
and discovery strategies based on concepts of “one-target, one-disease” are proving increas-
ingly unsuccessful. Metabolomics has driven an interest in agents that modulate multiple tar-
gets simultaneously. Targeting cellular function as a system, rather than at a single-target,
may lead to novel classes of effective multi-targeted drugs with fewer side-effects.*
*Paragraph adapted from Schrattenholz A, et al: Methods Mol Biol. 662:29-58, 2010.